All lobbying filings

Holland & Knight LLP

Holland & Knight LLP filed a Q3 report for Viatris Inc. on October 18, 2025, reporting $50,000 in lobbying income.

Lobbying for Viatris Inc. · Pharmaceutical company

As filed: HOLLAND & KNIGHT LLP for VIATRIS INC.

All filings by Holland & Knight LLP · Everything Viatris Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 18, 2025

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Pharmacy

S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.

Bills named in this filing 1

S. 1302
Increasing Transparency in Generic Drug Applications Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.